Successfully reported this slideshow.

Ophthalmic Innovation 2016 - "A View From The NEI"

2

Share

Loading in …3
×
1 of 12
1 of 12

Ophthalmic Innovation 2016 - "A View From The NEI"

2

Share

Download to read offline

Ophthalmic Innovation 2016 - "A View From The NEI"

Presenter:
Mala Dutta, PhD, Lead, Office of Translational Research, National Eye Institute


Powered by:
Healthegy

For more ophthalmology innovation
Visit us at www.ois.net




Ophthalmic Innovation 2016 - "A View From The NEI"

Presenter:
Mala Dutta, PhD, Lead, Office of Translational Research, National Eye Institute


Powered by:
Healthegy

For more ophthalmology innovation
Visit us at www.ois.net




More Related Content

Related Books

Free with a 14 day trial from Scribd

See all

Related Audiobooks

Free with a 14 day trial from Scribd

See all

Ophthalmic Innovation 2016 - "A View From The NEI"

  1. 1. Ophthalmic Innovation 2016: View from the National Eye Institute Mala Dutta, Ph.D. Lead, Office of Translational Research National Eye Institute, NIH
  2. 2. NEI Operating Budget in FY2016: $707 million1/ • NEI Research Project Grants: The biggest part of NEI budget. • Non-dilutive funding: Grantee keeps the IP (Bayh-Dole Act). 1/ Post HHS Secretary’s Transfer
  3. 3. The NEI Audacious Goal Initiative “Regenerate neurons and neural connections in the eye and visual system” Three Focus areas of AGI • photoreceptor loss • ganglion cell injury • optic nerve regeneration • Addresses pathogenesis of many vision diseases and conditions. AMD, Glaucoma, LHON, Retinal Degenerations, etc. • Model for regenerative therapy beyond vision: CNS & spinal cord. • Translate basic science of plasticity into effective treatments for strabismus, amblyopia, and central visual processing.
  4. 4. The NEI Audacious Goal Initiative Workshops to date: •4 Experts Workshops (SfN & ARVO) / 2 Town Halls at ARVO •2 white papers, next one in J. of Neuroscience For more information please visit: nei.nih.gov/audacious 2 FOAs •“Functional Imaging of the Visual System” o 5 awards, May 2015, ~$4M total/yr. for 5 yrs. •“Identifying Neural Regeneration Factors in the Visual System” o 6 awards, Sept 2016, ~$4M total/yr. for 3 yrs.
  5. 5. Convergence of initiatives • The NEI Audacious Goals Initiative  Catalyzing neuroregenerative medicine for vision • The BRAIN Initiative at NIH-2014  Providing new tools and technologies to understand and modulate brain circuitry • NIH Precision Medicine Initiative – 2015:  Medical treatments of the future based on personal genetic information • NCATS Tissue Chip at NIH  Developing 3-D platforms engineered to support living human tissues and cells to improve drug screening
  6. 6. NEI Translational Research Program (R24 Grants) • Multidisciplinary and collaborative research projects • $10M budget: 6-7 ongoing projects; $1.5M/year/ 5 years. Non renewable grants • Proof of concept Preclinical development IND/IDE submission NEI U10/UG1 Clinical Vision Research Grant /R34 Clinical Study Development Grant. • Current portfolio: small molecule photo switches for outer- retinal blindness; gene therapy for a number of ocular disorders (ABCA4-associated disorders, autosomal RP, and achromotopsia); and microRNAs for potent anti-angiogenesis. Program Director: Neeraj Agarwal, PhD. agarwalnee@nei.nih.gov Success stories: • Emory University: Nanoparticle preparation of chemotherapeutic agents microneedles to inject drugs into suprachoroidal space Start-up Clearside Biomedical • Univ of Miami: Leber Hereditary Optic Neuropathy (LHON) gene therapy product, AAV- ND4 Phase 1 Clinical trial - follow-up U10 grant.
  7. 7. Small Business Grants (SBIR & STTR) Program Director: Jerry Wujek, PhD, wujekjer@nei.nih.gov Support small companies to transform innovative ideas into ophthalmic drugs, medical instruments, or assistive devices that help people. • $20 M/year, 70 small companies • Regulatory Assistance Program Success Stories: • VisionQuest Biomedical, LLC: Telemedicine system for real-time, large scale eye screening at sustainable cost. • Photoswitch Biosciences: Small-molecule therapeutic photo-switch channel to restore vision in retinal degenerative disease. • Parion Sciences, Inc: Epithelial sodium channel antagonist to regulate salt & water transport as a therapeutic for dry eye.
  8. 8. Cell and Gene Therapy in Intramural Program iPSC Stem Cell Therapy • Use iPS cells to create RPE patch to treat AMD •A major NEI intramural basic to clinical initiative •IND for human trial in 2017/2018 •The leading NIH program for neural transplantation Human Ocular Gene Therapy X-Linked Retinoschisis (XLRS): Phase I / IIa. •One of first NIH in vivo gene therapy programs • Clinical trials with XLRS patients ongoing X-Linked Retinitis Pigmentosa RPGR Gene Therapy •Pre-Clinical Phase, murine animal model •AAV-based therapeutic rescue
  9. 9. NEI commits nearly $50M in annual clinical trial support NEI supported DRCR.net : rapid implementation of protocols for large-scale clinical trials •Prompt versus Deferred Panretinal Photocoagulation (PRP) with Intravitreal Ranibizumab (Lucentis) with for Proliferative Diabetic Retinopathy (PDR) • Phase III, prospective, multicenter randomized • Results: Over 2 years, deferred w/Lucentis beneficial • This trial marks the first major advance in PDR in 40 years • A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (DME) • Safety and efficacy • Results: Over 2 years, all 3 improved vision in DME when starting vision loss milder. More advanced vision loss, Eylea clear advantage • This study is critical for doctors and patients to make informed decisions in choosing treatment for diabetic macular edema. Extramural Clinical Trial Support
  10. 10. Nurturing Vision Research Talent NEI trains students, fellows and clinicians in vision research. • Fellowship training in basic science and clinical research engages graduate students, baccalaureate fellows, postdoc fellows and clinicians in vision research. • Diversity in Vision Research and Ophthalmology (DIVRO) recruits students from underrepresented groups for summer internship program.
  11. 11. End of Slides Ophthalmic Innovation 2015: View from the National Eye Institute. Paul A. Sieving, MD, PhD.

Editor's Notes

  •  
  •  
  • ×